Trial Profile
International, Multicenter, Double-blind, Randomized, Placebo-controlled Phase 2a Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jan 2021
Price :
$35
*
At a glance
- Drugs BP 101 (Primary)
- Indications Decreased libido; Female sexual dysfunction
- Focus Therapeutic Use
- Sponsors Ivix
- 05 Jan 2021 According to an Ovoca Bio media release, upon confirming the submission, the Minzdrav will automatically commence a review process, which is expected to be a minimum of nine months duration.
- 05 Jan 2021 According to an Ovoca Bio media release, based on the two Phase 1 studies, a Phase 2a study and the pivotal Phase 3 study, the company has resubmitted the Marketing Authorisation (MA) to the Russian Ministry of Health (Minzdrav) on 30 Dec 2020. The MA submission was not granted following the identification of issues relating to the chemistry, manufacturing and controls (CMC) and labelling sections of the MA submission dossier.
- 15 Aug 2017 Status changed from active, no longer recruiting to completed.